Q3 EARNINGS: Qiagen facing HPV headwinds; Lombard, SnN, Teleflex
This article was originally published in Clinica
Executive Summary
Dutch molecular diagnostics specialist Qiagen posted an in-line third quarter, with sales of $336.8m and adjusted earnings of $0.27 per share bang on analyst consensus. However, the firm is facing a challenging human papillomavirus (HPV) testing market, where it has been forced to cut its prices due to competition. “US HPV [sales] declined faster than expected and should continue to be a drag on top-line growth in 2015,” wrote Goldman Sachs analyst Isaac Ro. “However, [the franchise] is now small enough as a percentage of total sales to be offset by other growth opportunities.”